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Increased CSF levels of aromatic amino
acids in hip fracture patients with delirium
suggests higher monoaminergic activity
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Abstract
Background: To examine whether delirium in hip fracture patients was associated with changes in the levels
of amino acids and/or monoamine metabolites in cerebrospinal fluid (CSF) and serum.
Methods: In this prospective cohort study, 77 patients admitted with an acute hip fracture to Oslo University
Hospital, Norway, were studied. The concentrations of amino acids in CSF and serum were determined by high
performance liquid chromatography. The patients were assessed daily for delirium by the Confusion Assessment
Method (pre-operatively and post-operative day 1–5 (all) or until discharge (delirious patients)). Pre-fracture
dementia status was decided by an expert panel. Serum was collected pre-operatively and CSF immediately
before spinal anesthesia.
Results: Fifty-three (71 %) hip fracture patients developed delirium. In hip fracture patients without dementia
(n = 39), those with delirium had significantly higher CSF levels of tryptophan (40 % higher), tyrosine (60 % higher),
phenylalanine (59 % higher) and the monoamine metabolite 5-hydroxyindoleacetate (23 % higher) compared to
those without delirium. The same amino acids were also higher in CSF in delirious patients with dementia (n = 38).
The correlations between serum and CSF amino acid levels were poor.
Conclusion: Higher CSF levels of monoamine precursors in hip fracture patients with delirium suggest a higher
monoaminergic activity in the central nervous system during delirium in this patient group.
Background
Delirium, an acute brain dysfunction resulting in a
change in cognition and attention, is often precipitated
by emergency hospitalization and surgery [1]. Delirium
is especially common among elderly patients, and as
many as 40–50 % of acutely hospitalized patients with
hip fracture develop delirium [2, 3]. Although an in-
creased awareness of risk factors of delirium may reduce
its incidence, there is no effective pharmacological treat-
ment once delirium has developed [1, 4]. The patho-
physiology of delirium is poorly understood [5].
Aromatic amino acids are precursors for the mono-
amines dopamine, noradrenaline and serotonin, which
have important roles in attention and cognition and have
thus been of interest in delirium research [6]. The rate
of monoamine synthesis in the brain is determined by
the concentration of aromatic amino acids, because rate-
limiting enzymes (tryptophan hydroxylase and tyrosine
hydroxylase) are not saturated with substrate under
physiological conditions [7]. Phenylalanine and tyrosine
(dopamine and noradrenaline precursors) levels have
been found to be elevated in serum in patients with de-
lirium [8–10]. Both increased and decreased serum
levels of the serotonin precursor tryptophan have been
reported in patients with delirium [10, 11]. However,
whether such changes in serum levels translate to the
central nervous system is unclear.
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Amino acid levels in CSF have to our knowledge never
been assessed in patients with delirium. The purpose of
this study was to examine if delirium was associated
with changes in the levels of amino acids and/or
monoamine metabolites in CSF.
Methods
We included hip fracture patients that were participants
in Oslo Orthogeriatric Trial (OOT), a randomized con-
trolled trial evaluating the orthogeriatric service at Oslo
University Hospital [12]. Enrollment in OOT took place
from September 2009 through January 2012, and all
patients with a hip fracture were eligible, irrespective of
age, pre-fracture function, cognitive status, and accom-
modation. Patients were excluded if the fracture was
caused by a high energy trauma (defined as a fall from
more than one meter) or if the patient was terminally ill.
Trial inclusion took place in the emergency room by the
orthopedic surgeon on call. The majority of patients
underwent surgery following spinal anesthesia, and CSF
was sampled immediately before administration of the
anesthetic agent.
Measurements and procedures
The patients were screened for delirium once daily with
the Confusion Assessment Method [13] (CAM); pre-
operatively and until day 5 post-operatively (all patients)
or until discharge (delirious patients). CAM scores were
based on an interview with the patient, including tests of
cognition, attention and alertness (digit span test, orien-
tation and delayed recall), information from close rela-
tives and nurses, and scrutinization of hospital records
from the previous 24 h. A geriatrician (LOW) and a
trained research nurse performed the assessments. If the
research nurse was unsure about the delirium diagnosis,
the geriatrician was consulted.
An expert panel consisting of a geriatrician (TBW)
and a geriatric psychiatrist (KE) decided whether the
patients fulfilled the ICD 10 criteria for dementia prior
to the fracture. The expert panel used all available in-
formation, including the Informant Questionnaire on
Cognitive Decline in the Elderly [14, 15] (IQCODE), case
notes, and cognitive tests performed at the follow up
controls in the OOT (Mini-Mental state examination
(MMSE) [16], clock drawing test [17], the 10 word
test from the Consortium to establish a Registry for
Alzheimer’s disease battery (CERAD) [18] and The
Clinical Dementia Rating scale (CDR) [19]). Cases with
disagreement were discussed until a consensus was
reached. More details regarding the delirium assessments
and other cognitive measures have previously been
published [12, 20]. Proxies were interviewed regarding
pre-fracture Activities of Daily living (Barthel ADL Index)
[21]. Comorbid conditions were quantified using the
Charlson Comorbidity Index [22]. The Acute Physio-
logical and Chronic Health Evaluation II (APACHE II)
[23] score was calculated as a measure of physiological
disturbance on admission to the hospital.
Sample collection and handling
CSF was collected in polypropylene tubes and was cen-
trifuged as soon as possible. The supernatant was stored
in aliquots of 1000 μl at −80 °C. Serum was collected
pre-operatively by venous puncture. The sample tubes
stood in the vertical position for 30 min at room
temperature for clotting before centrifugation. Aliquots
of 200–500 μl were then stored at −80 °C in polypropyl-
ene tubes.
Sample selection
CSF was obtained from 143 hip fracture patients (Fig. 1).
We wanted to compare delirium patients with patients
who were free from any delirious symptoms, and pa-
tients with subsyndromal delirium (defined as at least
one positive CAM item, but never full delirium) were
therefore excluded. Patients with unknown delirium
status were also excluded.
We wanted all combinations of delirium and dementia
status represented:
1. no delirium/no dementia
2. delirium/no dementia
3. no delirium/dementia
4. delirium/dementia
There was a surplus of samples from group 1 and 4,
and we selected random samples from these two groups.
Amino acid analysis
Samples of CSF and serum were thawed on ice, and
18 μL of CSF were mixed with 2 μL of α-aminoadipate
(internal concentration standard), 200 μmol/L in sodium
azide, 2 % (weight/volume), giving a final concentration of
the internal standard of 20 μmol/L. Serum was mixed 1:1
with α-aminoadipate, 200 μmol/L in sodium azide, 2 %.
The sodium azide was added to avoid bacterial growth.
Amino acids were analyzed by high-performance liquid
chromatography (HPLC) and fluorescence detection
after pre-column derivatization with o-phthaldialdehyde
as described by Dahlberg et al. [24]. The analyses
were done blindly with respect to clinical data.
Monoamine metabolites analysis
5-hydroxyindoleacetic (5-HIAA) and homovanillic acid
(HVA) were separated by HPLC using a Zorbax Eclipse
XDB-C8 column, and measured by electrochemical
detection. Oxidation potential was set at 0.6 V after
samples had been deproteinized with sulphosalicylic
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acid, as previously described [25, 26]. Quantification was
done by measuring peak heights relative to the internal
standard 5-methylserotonin. The 5-HIAA and HVA
analyses were done blinded to clinical data. 5-HIAA and
HVA were analyzed in CSF only.
Data presentation and statistics
In our primary analyses, we compared the levels of
amino acids in CSF and serum between patients with
and without delirium by Mann–Whitney U tests. Since
dementia is associated with neurodegeneration and the
cerebral substrate for delirium might be different for
subjects with or without a dementia disorder, these ana-
lyses were carried out stratified by pre-fracture dementia
status. In a secondary analysis we then divided the hip
fracture patients into three subgroups:
1. Ongoing delirium – patients who had delirium when
CSF was taken.
2. Incident delirium – patients who were free from
delirium when CSF was taken, but developed
delirium later.
3. Never delirium – patients who never experienced
any symptoms of delirium.
Correlations between amino acid levels in CSF and
serum were evaluated with Spearman’s correlation
coefficient.
To assess the relationship between the amino acids
and delirium when adjusting for other covariates, we
carried out logistic regression analyses. We made separ-
ate regression models for each amino acid/monoamine
metabolite, however limited to those identified in univar-
iate analyses as having the largest differences between
patients with and without delirium. “Delirium anytime”
was the outcome variable in all models. As covariates we
included variables known to be associated with delirium;
age, gender, APACHE II (Acute Physiology and Chronic
Health Evaluation II), Barthel ADL (Activities of Daily
Living) and CCI (Charlson Comorbidity Index) scores.
Due to the exploratory nature of this study, correction
for multiple comparisons were not applied. All statistical
analyses were performed using IBM SPSS Statistics
version 20.
Results
In total, 77 CSF samples were analyzed and 53 of the
samples were from patients with delirium. Patients with
delirium were older, had more often dementia, had
Included in OOT (n=332)
Excluded (n=189)
- Sent to other hospital for surgery - 21
- Epidural anesthesia - 2
- General anesthesia  - 20
- Not operated - 5
- CSF not taken - 141
Number with CSF sample (N=143)
Excluded (n=33)
- Subsyndromal delirium - 23
- Insufficient sample - 7
- Delirium status unknown - 3
Number of CSF samples available 
(N=110)
Number of CSF samples selected for 
analyses (N=77)
Not selected for analysis (n=33)
- patients with dementia and delirium - 12
- patients with no dementia and no delirium - 21
No delirium (N=24) Delirium (N=53)
Fig. 1 Flow diagram showing selection of CSF samples from hip fracture patients. OOT = Oslo Orthogeriatric Trial
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higher APACHE II and more ADL impairment com-
pared to patients without delirium (Table 1). Twenty-
nine of the samples were from patients with ongoing
delirium, 21 from patients with incident delirium and 24
from patients who never developed delirium (preopera-
tive delirium status unknown in three patients).
CSF levels of amino acids and monoamine metabolites
In patients without pre-fracture dementia (n = 39), those
with delirium had significantly higher levels of trypto-
phan (40 % higher, Table 2), tyrosine (60 % higher),
phenylalanine (59 % higher), and methionine (29 %
higher). In patients with pre-fracture dementia (n = 38)
the same four amino acids were also highest in delirious
patients, however statistically significant only for tyro-
sine, phenylalanine and methionine. When the patients
were stratified by delirium status at the time of sam-
pling, we found that these amino acids tended to be
highest in the group of patients with incident delirium,
both in patients with and without dementia (Fig. 2).
In patients without dementia, CSF levels of 5-HIAA
were significantly higher in patients with delirium, paral-
leling the increased level of tryptophan in this group
(Table 2, Fig. 3). In contrast, the level of HVA was not
significantly different between the groups. In patients
with dementia there was no significant difference
between patients with or without delirium, with respect
to 5-HIAA or HVA.
In regression analyses, tryptophan, tyrosin, phenylalan-
ine, methionine and 5-HIAA remained significantly
associated with delirium status in patients free from de-
mentia when adjusting for age, gender, ADL, Charlson
and APACHE II (Table 3). The sample size was insuffi-
cient to carry out regression analyses in the stratum with
dementia.
Most amino acids were higher in patients without pre-
fracture dementia than in those with dementia, and this
difference was statistically significant for asparagine,
glutamate, glutamine, tyrosine, alanine, tryptophan, valine,
and phenylalanine. HVA (median 184 vs 118 nmol/L, p =
0.005) and 5-HIAA (median 147 v 104 nmol/L, p = 0.002)
were also significantly higher in patients without
chronic cognitive impairment.
When hip fracture patients with and without dementia
were pooled together, the only significant difference in
CSF was a higher methionine concentration in patients
with delirium compared to patients without (median 4.0
vs 3.1 μmol/L, p = 0.002).
Serum levels of amino acids. Correlation with CSF levels
Pre-operative serum was available for 44 patients. There
were no significant differences between groups except
for taurine which was higher in demented patients with-
out delirium than in demented patients with delirium
(median 8 v 7 μmol/L, p = 0.047). A significant correl-
ation between serum and CSF levels of amino acids was
observed only for valine (r = 0.38, p = 0.01), glutamine
(r = 0.44, p = 0.003) and isoleucine (r = 0.37, p = 0.02).
Discussion
The main finding in this study was higher CSF levels of
tryptophan, tyrosine, phenylalanine, methionine and 5-
HIAA in hip fracture patients with delirium and this
remained a significant finding also in adjusted analyses.
The highest levels of these amino acids were seen in
patients with incident delirium, and this pattern was
similar in patients with and without dementia. To our
knowledge this is the first study of CSF levels of
amino acids in patients with delirium, and the results
might contribute to the understanding of delirium
pathophysiology.
An increased level of tryptophan has been linked to in-
creased formation of serotonin in the brain, because
tryptophan hydroxylase, the rate-limiting enzymatic step
in serotonin synthesis, is not saturated with substrate
under physiological conditions (for review, see Fernstrom
[27]). We also found a significantly increased level of
the serotonin metabolite 5-HIAA in non-demented
patients with delirium. This paralleled the increased
CSF level of tryptophan in the same group, suggesting
(in line with Fernstrom [27]) that an increased level
of tryptophan leads to increased formation and turn-
over of serotonin. Our data therefore supports a no-
tion of increased serotonergic neurotransmission in
patients with delirium.
We also found that patients with delirium had higher
CSF levels of tyrosine and its immediate precursor,
phenylalanine. An increased concentration of tyrosine
would be expected to cause increased formation of
dopamine, and our findings are in line with the theory
of dopamine excess in delirium [6]. Although we found
an increased concentration of tyrosine, we did not see
the same relationship between CSF levels of tyrosine and
Table 1 Baseline characteristics
No delirium
(n = 24)
Delirium
(n = 53)
P-value
Age, median (IQR) 84 (70–89) 86 (81–90) 0.21
Gender, male (%) 7 (29) 16 (30) 0.93
APACHE II, median (IQR)a 8 (6–10) 9 (8–11) 0.10
IQCODE, median (IQR) 3.1 (3.0–3.6) 4.3 (3.3–4.8) <0.001
Dementia (%) 3 (13) 35 (66) <0.001
ADL, median (IQR) 19.5 (18–20) 16 (12–19) <0.001
CCI, median (IQR) 1 (0–2) 1 (0–2) 0.96
aArterial blood gas and hematocrit omitted from formula
IQR interquartile range, APACHE II Acute Physiology and Chronic Health
Evaluation II, IQCODE Informant Questionnaire on Cognitive Decline in the
Elderly, ADL activities of daily living, CCI Charlson Comorbidity Index score
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the dopamine metabolite HVA that we did for trypto-
phan and serotonin metabolite 5-HIAA. Methionine
contributes a methyl moiety in the synthesis of nor-
adrenaline from dopamine [28]. Therefore the increase
in methionine could allow for an increased metabolism
of dopamine into noradrenaline.
Comparison with other studies
Our results suggest higher monoaminergic activity in de-
lirious patients. One of the very few published animal
studies in delirium gives support to our finding; in a rat
model delirium was associated with increased CSF levels
of the serotonine metabolite 5-HIAA and the dopamine
metabolites HVA and 3,4-dihydroxyphenylacetic acid,
and treatment with a selective serotonin 5HT1A antag-
onist reduced delirium symptoms in the same animals
[29]. Further support for increased serotonergic neuro-
transmission in delirium comes from drug trials. A re-
cent double-blind randomized controlled study in hip
fracture patients showed that post-operative adminis-
tration of the serotonin antagonist ondansetron led to a
lower incidence and shorter duration of post-operative
delirium compared to placebo [30]. In contrast, another
randomised controlled trial found an increased risk of
hyperactive delirium in patients undergoing major
elective surgery who were given tryptophan postoper-
atively [31].
Although this is the first study of amino acids in CSF,
there are several reports of changes in amino acid con-
centrations in serum from patients with delirium. Both
higher and lower levels of tryptophan have been associ-
ated with delirium [9, 10, 32–34]. Serum phenylalanine
and tyrosine have been reported to be increased in
delirium [8–10]. In our study we found only minor dif-
ferences between serum levels of amino acids between
patients with and without delirium. The poor correl-
ation between serum and CSF levels of amino acids in
the present study illustrates the difficulty of making
inferences about brain levels of amino acids from their
serum levels.
CSF monoamine metabolites HVA and 5-HIAA have
been analysed in one study each in delirium. A Mexican
study published in 2008 included 51 patients (31 with
delirium) with acute brain infection [35]. The patient
Table 2 Concentration of amino acids and monoamine metabolites in CSF
No dementia (n = 39) Dementia (n = 38)
No delirium
(n = 21)
Delirium
(n = 18)
p-value No delirium
(n = 3)
Delirium
(n = 35)
p-value
Amino acids
Alanine, μmol/L 25 (20–36) 27 (19–43) 0.39 17 (16–17) 25 (20–32) 0.128
Arginine, μmol/L 12 (11–16) 12 (9–17) 0.53 9 (9–9) 12 (9–13) 0.25
Aspargine, μmol/L 5 (4–6) 6 (3–8) 0.51 3 (3–3) 4 (4–5) 0.07
Glutamate, μmol/L 0.7 (0.4–1.8) 0.9 (0.6–1.7) 0.44 0.6 (0.3–0.6) 0.5 (0.4–0.8) 0.91
Glutamine, μmol/L 460 (360–528) 505 (384–588) 0.34 284 (278–284) 385 (321–457) 0.045
Glycine, μmol/L 28 (24–35) 27 (21–38) 0.51 23 (22–23) 28 (25–36) 0.72
Isoleucine, μmol/L 5 (3–6) 6 (3–10) 0.11 5 (4–5) 6 (4–7) 0.88
Leucine, μmol/L 11 (7–15) 12 (9–22) 0.38 12 (9–12) 13 (9–16) 0.98
Lysine, μmol/L 13 (11–15) 13 (10–17) 0.77 10 (10–10) 12 (10–15) 0.48
Methionine, μmol/L 3 (2–4) 4 (3–6) 0.030 3 (1–3) 4 (3–5) 0.029
Phenylalanine, μmol/L 9 (7–13) 14 (9–19) 0.014 6 (6–6) 9 (7–11) 0.021
Serine, μmol/L 17 (14–18) 15 (10–17) 0.21 13 (13–13) 15 (12–18) 0.92
Taurine, μmol/L 8 (7–11) 8 (6–10) 0.64 8 (7–8) 7 (5–9) 0.71
Tryptophan, μmol/L 0.8 (0.6–1.0) 1.1 (0.7–1.5) 0.042 0.6 (0.4–0.6) 0.7 (0.6–0.9) 0.15
Tyrosine, μmol/L 5 (4–7) 8 (5–11) 0.028 4 (3–4) 5 (4–7) 0.041
Valine, μmol/L 16 (13–25) 18 (14–31) 0.32 12 (12–12) 15 (12–21) 0.47
Monoamine metabolites
HVA, nmol/L 170 (102–280) 204 (125–250) 0.42 134 (67–134) 114 (68–179) 0.88
5HIAA, nmol/L 138 (111–156) 170 (119–261) 0.048 99 (81–99) 104 (68–(140) 0.84
IQR interquartile range, HVA homovanillic acid, 5HIAA 5-hydroxyindoleacetic
Concentration of amino acids and monoamine metabolites in hip fracture patients with and without delirium, stratified by pre-fracture dementia status. All values
are median (IQR). P-values were calculated using Mann–Whitney U test. P-values below 0.05 are in bold
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cohort was different from ours (mean age 36, high
prevalence of HIV). There was no significant difference
in HVA levels between patients with and without delir-
ium. Subgroup analyses revealed, however, that patients
with psychotic symptoms had significantly higher levels
of HVA compared to patients without such symptoms
[35]. CSF levels of 5-HIAA was measured in a Finnish
study of 69 patients with delirium and 14 healthy con-
trols. 5-HIAA was higher in delirious patients than in
controls, but this difference was significant only in two
subgroups of patients: those with multi-infarct dementia,
and those with no apparent CNS disease [36].
We found that both amino acids and monoamine me-
tabolites were reduced in patients with dementia, as also
reported in other studies [37, 38]. Since dementia is a
strong risk factor for delirium, most patients with delir-
ium had dementia and most patients without dementia
were free from delirium. Since delirium seems to be as-
sociated with an increase in the same amino acids that
are decreased in dementia, delirium and dementia might
level each other out in analyses not taking chronic cog-
nitive decline into account. This was clearly illustrated
in our study. When patients with and without dementia
were analyzed together, only methionine (in CSF) and
Fig. 3 Levels of monoamine metabolites in CSF. Levels of monoamine metabolites in CSF in hip fracture patients free from dementia, stratified on
delirium status at the time of CSF sampling. The horizontal line represents the median. HVA = Homovanillic Acid. 5HIAA = 5-hydroxyindoleacetic
Fig. 2 Levels of aromatic aminoacids in CSF. Levels of aromatic amino acids in CSF of hip fracture patients free from dementia, stratified on
delirium status at the time of CSF sampling. The horizontal line represents the median
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taurine (in serum) were significantly different between
patients with and without delirium. In stratified analyses,
however, a similar pattern emerged in both groups.
Strength and weaknesses
Many of the candidate biomarkers in delirium are also
influenced by dementia [39] and the main strength of
our study was the relatively large sample size, making it
possible to select CSF samples for analyses stratified by
pre-fracture cognitive status. Theoretically, it is likely
that some neurotransmitters are involved in initiating
delirium whereas others play a role in severity, maintain-
ing or resolution of the delirious episode. We were able
to stratify our analyses according to delirium status at
the time of sampling, and thus able to demonstrate that
the monoaminergic activation seems to be at the highest
prior to a delirious episode. We consider this a finding
of possible importance. A weakness with our study was
that not all delirium assessments were done by a geria-
trician. Since patients were assessed weekdays only, it is
possible that brief episodes of delirium during weekends
have been missed. The cross-sectional design is another
weakness of our study; however, a longitudinal study
with repeated CSF sampling from patients with delirium
will be very hard to perform. We analyzed several amino
acids, and there is an increased risk of false positive
findings. Since hip fracture is an acute event, objective
cognitive testing prior to the fracture is not possible. We
believe our approach with a consesus based dementia
diagnosis is superior to the use of IQCODE alone.
Nevertheless, the retrospective classification of demen-
tia is a weakness of our study. We also have no infor-
mation regarding dementia etiology.
Conclusion
This first study of CSF levels of amino acids in delirium
suggests increased monoaminergic activity is associated
with delirium in hip fracture patients.
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